skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

4 Total results for product and free and sample content found

Datamonitor Healthcare

EULAR: Pfizer’s Xeljanz will be the first-in-class JAK inhibitor in PsA, but faces challenges at launch

By Ines Mihel 22 Jun 2017

EULAR: Pfizer’s Xeljanz will be the first-in-class JAK inhibitor in PsA, but faces challenges at launch

Topic Comment wire

View article

Datamonitor Healthcare

Disappointing Translarna failure is an isolated event for CF pipeline

30 Mar 2017

PTC Therapeutics announced the failure of its ACT CF trial of Translarna (ataluren) in nonsense mutation cystic fibrosis (nmCF) patients, bringing a halt to any further planned developmental activities in the indication. Although there was a slight treatment effect, Translarna failed to significantly improve pulmonary measures compared to placebo.

Topic Comment wire

View opinion

Datamonitor Healthcare

Pfizer suspends the development of bococizumab

By Sita Indrakumar 03 Nov 2016

Pfizer has suspended the global development of its pipeline proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, bococizumab, due to a lack of predicted value.

Topic Drug approval Comment wire

View opinion

Datamonitor Healthcare

Newly approved and late-phase biologics and eosinophilic asthma

25 May 2016

Newly approved and late-phase biologics and eosinophilic asthma

Data presented at ATS 2016 support the use of biologics in severe refractory eosinophilic asthma, and will inform the stringent formulary access policies expected to be implemented by payers for these high-cost therapies.

Single report

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Contact Customer Services

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now